<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64330</article-id><article-id pub-id-type="doi">10.7554/eLife.64330</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-189797"><name><surname>Mast</surname><given-names>Alan E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3740-0318</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-215827"><name><surname>Wolberg</surname><given-names>Alisa S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2845-2303</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-215828"><name><surname>Gailani</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-189791"><name><surname>Garvin</surname><given-names>Michael R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2204-7569</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-189792"><name><surname>Alvarez</surname><given-names>Christiane</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-189796"><name><surname>Miller</surname><given-names>J Izaak</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-189794"><name><surname>Aronow</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-189147"><name><surname>Jacobson</surname><given-names>Daniel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9822-8251</contrib-id><email>jacobsonda@ornl.gov</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Versiti Blood Research Institute, Department of Cell Biology Neurobiology and Anatomy Medical College of Wisconsin</institution><addr-line><named-content content-type="city">Milwaukee</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology and Laboratory Medicine and UNC Blood Research Center</institution><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Oak Ridge National Laboratory, Biosciences Division</institution><addr-line><named-content content-type="city">Oak Ridge</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>University of Tennessee Knoxville, The Bredesen Center for Interdisciplinary Research and Graduate Education</institution><addr-line><named-content content-type="city">Knoxville</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Biomedical Informatics, Cincinnati Children’s Hospital Research Foundation</institution><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>University of Cincinnati</institution><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>University of Tennessee Knoxville, Department of Psychology</institution><addr-line><named-content content-type="city">Knoxville</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>van der Meer</surname><given-names>Jos WM</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64330</elocation-id><history><date date-type="received" iso-8601-date="2020-10-26"><day>26</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-06"><day>06</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Mast et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Mast et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64330-v3.pdf"/><abstract><p>Extensive fibrin deposition in the lungs and altered levels of circulating blood coagulation proteins in COVID-19 patients imply local derangement of pathways that limit fibrin formation and/or promote its clearance. We examined transcriptional profiles of bronchoalveolar lavage fluid (BALF) samples to identify molecular mechanisms underlying these coagulopathies. mRNA levels for regulators of the kallikrein–kinin (C1-inhibitor), coagulation (thrombomodulin, endothelial protein C receptor), and fibrinolytic (urokinase and urokinase receptor) pathways were significantly reduced in COVID-19 patients. While transcripts for several coagulation proteins were increased, those encoding tissue factor, the protein that initiates coagulation and whose expression is frequently increased in inflammatory disorders, were not increased in BALF from COVID-19 patients. Our analysis implicates enhanced propagation of coagulation and decreased fibrinolysis as drivers of the coagulopathy in the lungs of COVID-19 patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>coagulation</kwd><kwd>fibrinolysis</kwd><kwd>bronchoalvelolar</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006228</institution-id><institution>Oak Ridge National Laboratory</institution></institution-wrap></funding-source><award-id>LOIS:10074</award-id><principal-award-recipient><name><surname>Garvin</surname><given-names>Michael R</given-names></name><name><surname>Miller</surname><given-names>J Izaak</given-names></name><name><surname>Jacobson</surname><given-names>Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U24 HL148865</award-id><principal-award-recipient><name><surname>Aronow</surname><given-names>Bruce</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL068835</award-id><principal-award-recipient><name><surname>Mast</surname><given-names>Alan E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL143403</award-id><principal-award-recipient><name><surname>Wolberg</surname><given-names>Alisa S</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL126974</award-id><principal-award-recipient><name><surname>Wolberg</surname><given-names>Alisa S</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL140025</award-id><principal-award-recipient><name><surname>Gailani</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>3RF1AG053303-01S2</award-id><principal-award-recipient><name><surname>Jacobson</surname><given-names>Daniel</given-names></name><name><surname>Garvin</surname><given-names>Michael R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transcription changes in cells taken from bronchoalveolar fluid of COVID-19 patients indicate severe disruption of coagulation and fibrinolytic pathways in the lung and suggest similar processes in other organs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The bradykinin storm model for COVID-19 pathogenesis was recently developed from our analyses of gene expression, clinical, autopsy, pathology, and ChIP-Seq data (<xref ref-type="bibr" rid="bib16">Garvin et al., 2020</xref>). Several clinical studies by other groups have demonstrated positive results from therapeutic interventions predicted by our model (<xref ref-type="bibr" rid="bib11">Entrenas Castillo et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">van de Veerdonk et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020</xref>). Here, we extend this model to include the concurrent dysregulation of the coagulation and fibrinolytic pathways.</p><p>SARS-CoV-2 displays considerable tissue tropism (<xref ref-type="bibr" rid="bib1">Adachi et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Barton et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Su et al., 2020</xref>; <xref ref-type="bibr" rid="bib65">Xu et al., 2020</xref>). The lungs are often affected with disease that can range from mild pneumonia, to severe dyspnea and hypoxia, to critical respiratory failure, shock, and multiorgan failure. The time course for the development of severe disease is typically 8–12 days, but some patients rapidly deteriorate about 7 days following development of symptoms. Lung tissue from people who died from COVID-19 has pauci-inflammatory septal capillary injury and luminal and mural fibrin deposition in alveolar septal capillaries (<xref ref-type="bibr" rid="bib28">Lax et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Magro et al., 2020</xref>), thrombi in small- and medium-sized arteries (<xref ref-type="bibr" rid="bib28">Lax et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Magro et al., 2020</xref>), and fibrinous thrombi in small pulmonary arterioles with evidence of tumefaction of the endothelium (<xref ref-type="bibr" rid="bib9">Dolhnikoff et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Fox et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Geerdes-Fenge et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Lax et al., 2020</xref>). A report that administering tissue plasminogen activator (tPA) to dissolve fibrin transiently alleviates respiratory distress in COVID-19 patients supports the premise that fibrin deposition contributes to the respiratory failure (<xref ref-type="bibr" rid="bib61">Wang et al., 2020</xref>). Thus, it appears that COVID-19 hypoxemia stems at least partially from fibrin deposits surrounding alveoli that restrict oxygen transfer and microvascular thrombi that cause ventilation–perfusion defects.</p><p>Abnormal levels of circulating coagulation proteins are present in patients with COVID-19. Changes include increased levels of coagulation proteins associated with the acute phase response (e.g., fibrinogen and factor VIII) and endothelial activation (e.g., von Willebrand factor), as well as elevated biomarkers of coagulation activation (e.g., D-dimer) (<xref ref-type="bibr" rid="bib6">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Gattinoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Helms et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Middeldorp et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Panigada et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Zhou et al., 2020a</xref>; <xref ref-type="bibr" rid="bib22">Helms et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Middeldorp et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Panigada et al., 2020</xref>). Accordingly, thrombotic events have been detected in up to 30% of COVID-19 patients (<xref ref-type="bibr" rid="bib22">Helms et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Middeldorp et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Panigada et al., 2020</xref>) including large vessel occlusions such as deep vein thrombosis, pulmonary embolism, and ischemic stroke, as well as microvascular thrombosis and extravascular fibrin deposition in a variety of tissues including lung and skin (<xref ref-type="bibr" rid="bib22">Helms et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Middeldorp et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Panigada et al., 2020</xref>). Inappropriate fibrin deposition and thrombosis are thought to stem from the interaction of systemic (blood) changes with tissue-specific dysfunction. However, mechanisms that contribute to prevalence of thrombi and fibrin in the pulmonary vasculature and extravascular space, thought to be a major cause of morbidity and mortality in COVID-19, have remained elusive.</p><p>The goal of the present study was to identify changes in the lungs of patients with severe COVID-19 that could contribute to local derangement of hemostatic mechanisms. Bronchoalveolar lavage fluid (BALF) contains lung parenchymal, epithelial, and alveolar cells, as well as immune cells that infiltrate epithelial and luminal spaces. RNA sequencing of BALF provides a snapshot of the transcriptome at the interface where capillary gas exchange occurs and has been used to characterize lung function in many diseases (<xref ref-type="bibr" rid="bib20">Gu et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Jakieła et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Kahn et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Sengupta et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Sun et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Weigt et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Zhang et al., 2019</xref>). Here, we compared the transcriptional signatures of BALF from patients with COVID-19 and uninfected controls. Our analyses focused on transcripts for proteins that function in coagulation, fibrinolysis, and kinin formation in the lung to identify dysregulated mechanisms that may contribute to COVID-19 pathophysiology.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Changes in transcripts encoding proteins in the kallikrein–kinin/bradykinin system</title><sec id="s2-1-1"><title>Overview of pathways examined</title><p>The plasma kallikrein–kinin system is comprised of the protease precursors factor XII (FXII, encoded by F12) and prekallikrein (encoded by <italic>KLKB1</italic>) and the cofactor high-molecular-weight kininogen (HK, encoded by <italic>KNG1</italic>) (<xref ref-type="bibr" rid="bib48">Schmaier, 2016</xref>; <xref ref-type="bibr" rid="bib49">Schmaier et al., 2019</xref>). In healthy individuals, FXII and prekallikrein undergo reciprocal activation to the proteases FXIIa and kallikrein (<xref ref-type="bibr" rid="bib43">Revenko et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Schmaier, 2016</xref>). Kallikrein cleaves HK to liberate bradykinin, which contributes to setting vascular tone and permeability by interacting with bradykinin receptors (encoded by <italic>BDKRB1</italic> and <italic>BDKRB2</italic>) (<xref ref-type="bibr" rid="bib33">Marceau et al., 2020</xref>). This process is regulated by C1-Inhibitor (encoded by <italic>SERPING1</italic>) (<xref ref-type="bibr" rid="bib33">Marceau et al., 2020</xref>). Congenital C1-Inhibitor deficiency causes hereditary angioedema, which is characterized by bouts of bradykinin-induced soft tissue swelling (<xref ref-type="bibr" rid="bib5">Busse and Christiansen, 2020</xref>; <xref ref-type="bibr" rid="bib7">Cicardi and Zuraw, 2018</xref>). C1-Inhibitor in blood is primarily of hepatocyte origin, although it also is produced by other cell types including vascular endothelium (<xref ref-type="bibr" rid="bib41">Prada et al., 1998</xref>).</p></sec><sec id="s2-1-2"><title>Study findings</title><p>Transcripts encoding C1-Inhibitor were decreased 80-fold in BALF from COVID-19 patients (<xref ref-type="table" rid="table1">Table 1</xref>), raising the possibilities that contact activation-initiated thrombin generation is locally dysregulated and control of bradykinin production is compromised. Furthermore, the angiotensin-converting enzyme (ACE) that degrades bradykinin (<xref ref-type="bibr" rid="bib7">Cicardi and Zuraw, 2018</xref>; <xref ref-type="bibr" rid="bib8">Davin et al., 2019</xref>) was downregulated eightfold in COVID-19 BALF.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Differentially expressed coagulation genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Gene</th><th valign="top">Protein product</th><th valign="top">Mean COVID-19</th><th valign="top">Mean control</th><th valign="top">Fold change</th><th valign="top">Log2FC</th><th valign="top">FDR</th></tr></thead><tbody><tr><td valign="top"><italic>A2M</italic></td><td valign="top">α2-Macroglubulin</td><td valign="top">3.9</td><td valign="top">177.6</td><td valign="top">−43.5</td><td valign="top">−5.4</td><td valign="top">5.2E-15</td></tr><tr><td valign="top"><italic>BDKRB1</italic></td><td valign="top">Bradykinin receptor B1</td><td valign="top">3.3</td><td valign="top">0.0</td><td valign="top">258.9</td><td valign="top">8.0</td><td valign="top">4.3E-91</td></tr><tr><td valign="top"><italic>BDKRB2</italic></td><td valign="top">Bradykinin receptor B2</td><td valign="top">8.9</td><td valign="top">0.2</td><td valign="top">49.1</td><td valign="top">5.6</td><td valign="top">1.9E-40</td></tr><tr><td valign="top"><italic>F13A1</italic></td><td valign="top">Factor XIII-A subunit</td><td valign="top">2.5</td><td valign="top">9.2</td><td valign="top">−3.6</td><td valign="top">−1.8</td><td valign="top">2.6E-05</td></tr><tr><td valign="top"><italic>F13B</italic></td><td valign="top">Factor XIII-B subunit</td><td valign="top">0.6</td><td valign="top">0.0</td><td valign="top">117.8</td><td valign="top">6.9</td><td valign="top">2.7E-31</td></tr><tr><td valign="top"><italic>F12</italic></td><td valign="top">Factor XII</td><td valign="top">0.5</td><td valign="top">3.2</td><td valign="top">−4.4</td><td valign="top">−2.1</td><td valign="top">5.7E-10</td></tr><tr><td valign="top"><italic>F11</italic></td><td valign="top">Factor XI</td><td valign="top">6.6</td><td valign="top">0.1</td><td valign="top">81.2</td><td valign="top">6.3</td><td valign="top">7.9E-79</td></tr><tr><td valign="top"><italic>F10</italic></td><td valign="top">Factor X</td><td valign="top">3.2</td><td valign="top">0.0</td><td valign="top">169.9</td><td valign="top">7.4</td><td valign="top">7.9E-140</td></tr><tr><td valign="top"><italic>F9</italic></td><td valign="top">Factor IX</td><td valign="top">0.9</td><td valign="top">0.0</td><td valign="top">189.6</td><td valign="top">7.6</td><td valign="top">2.2E-39</td></tr><tr><td valign="top"><italic>F8</italic></td><td valign="top">Factor VIII</td><td valign="top">3.9</td><td valign="top">15.8</td><td valign="top">−4.6</td><td valign="top">−2.2</td><td valign="top">1.6E-40</td></tr><tr><td valign="top"><italic>F7</italic></td><td valign="top">Factor VII</td><td valign="top">10.1</td><td valign="top">0.0</td><td valign="top">363.5</td><td valign="top">8.5</td><td valign="top">2.9E-73</td></tr><tr><td valign="top"><italic>F5</italic></td><td valign="top">Factor V</td><td valign="top">9.7</td><td valign="top">6.8</td><td valign="top">1.4</td><td valign="top">0.5</td><td valign="top">0.13</td></tr><tr><td valign="top"><italic>F3</italic></td><td valign="top">Tissue Factor</td><td valign="top">4.2</td><td valign="top">3.8</td><td valign="top">-1.0</td><td valign="top">-0.01</td><td valign="top">1</td></tr><tr><td valign="top"><italic>F2</italic></td><td valign="top">Prothrombin</td><td valign="top">0.9</td><td valign="top">0.0</td><td valign="top">188.8</td><td valign="top">7.6</td><td valign="top">7.8E-67</td></tr><tr><td valign="top"><italic>FGA</italic></td><td valign="top">Fibrinogen Aα chain</td><td valign="top">3.4</td><td valign="top">0.0</td><td valign="top">322.5</td><td valign="top">8.3</td><td valign="top">3.4E-206</td></tr><tr><td valign="top"><italic>FGB</italic></td><td valign="top">Fibrinogen Bβ chain</td><td valign="top">3.7</td><td valign="top">0.0</td><td valign="top">303.9</td><td valign="top">8.2</td><td valign="top">2.4E-151</td></tr><tr><td valign="top"><italic>FGG</italic></td><td valign="top">Fibrinogen γ chain</td><td valign="top">0.7</td><td valign="top">0.0</td><td valign="top">85.4</td><td valign="top">6.4</td><td valign="top">4.8E-17</td></tr><tr><td valign="top"><italic>KLKB1</italic></td><td valign="top">Kallikrein B1</td><td valign="top">1.3</td><td valign="top">1.8</td><td valign="top">−1.4</td><td valign="top">−0.5</td><td valign="top">2.1E-01</td></tr><tr><td valign="top"><italic>KNG1</italic></td><td valign="top">Kininogen</td><td valign="top">3.3</td><td valign="top">0.0</td><td valign="top">190.7</td><td valign="top">7.6</td><td valign="top">4.2E-163</td></tr><tr><td valign="top"><italic>PLAT</italic></td><td valign="top">Tissue plasminogen activator</td><td valign="top">1.8</td><td valign="top">0.4</td><td valign="top">5.3</td><td valign="top">2.4</td><td valign="top">7.1E-24</td></tr><tr><td valign="top"><italic>PLAU</italic></td><td valign="top">Urokinase</td><td valign="top">3.8</td><td valign="top">158.3</td><td valign="top">−37.1</td><td valign="top">−5.2</td><td valign="top">8.2E-172</td></tr><tr><td valign="top"><italic>PLAUR</italic></td><td valign="top">Urokinase receptor</td><td valign="top">6.2</td><td valign="top">313.3</td><td valign="top">−42.1</td><td valign="top">−5.4</td><td valign="top">6.4E-286</td></tr><tr><td valign="top"><italic>PLG</italic></td><td valign="top">Plasminogen</td><td valign="top">2.2</td><td valign="top">0.0</td><td valign="top">75.3</td><td valign="top">6.2</td><td valign="top">7.3E-38</td></tr><tr><td valign="top"><italic>PROC</italic></td><td valign="top">Protein C</td><td valign="top">2.0</td><td valign="top">0.0</td><td valign="top">226.5</td><td valign="top">7.8</td><td valign="top">4.1E-158</td></tr><tr><td valign="top"><italic>PROCR</italic></td><td valign="top">Endothelial protein C receptor</td><td valign="top">1.7</td><td valign="top">57.9</td><td valign="top">−33.8</td><td valign="top">−5.1</td><td valign="top">1.9E-50</td></tr><tr><td valign="top"><italic>PROS1</italic></td><td valign="top">Protein S</td><td valign="top">3.2</td><td valign="top">195.3</td><td valign="top">−54.2</td><td valign="top">−5.8</td><td valign="top">1.1E-174</td></tr><tr><td valign="top"><italic>SERPINA5</italic></td><td valign="top">Protein C Inhibitor</td><td valign="top">2.7</td><td valign="top">0.0</td><td valign="top">786.8</td><td valign="top">9.6</td><td valign="top">5.4E-145</td></tr><tr><td valign="top"><italic>SERPINB2</italic></td><td valign="top">Plasminogen activator inhibitor-2</td><td valign="top">1.0</td><td valign="top">0.5</td><td valign="top">2.3</td><td valign="top">1.2</td><td valign="top">2.1E-01</td></tr><tr><td valign="top"><italic>SERPINC1</italic></td><td valign="top">Antithrombin</td><td valign="top">1.9</td><td valign="top">0.1</td><td valign="top">13.6</td><td valign="top">3.8</td><td valign="top">3.1E-31</td></tr><tr><td valign="top"><italic>SERPIND1</italic></td><td valign="top">Heparin cofactor II</td><td valign="top">3.0</td><td valign="top">0.0</td><td valign="top">94.0</td><td valign="top">6.6</td><td valign="top">2.2E-72</td></tr><tr><td valign="top"><italic>SERPINE1</italic></td><td valign="top">Plasminogen activator inhibitor-1</td><td valign="top">2.7</td><td valign="top">5.3</td><td valign="top">−1.8</td><td valign="top">−0.9</td><td valign="top">8.8E-02</td></tr><tr><td valign="top"><italic>SERPINF2</italic></td><td valign="top">α2-antiplasmin</td><td valign="top">5.4</td><td valign="top">8.2</td><td valign="top">−1.4</td><td valign="top">−0.5</td><td valign="top">1.1E-02</td></tr><tr><td valign="top"><italic>SERPING1</italic></td><td valign="top">C-1 inhibitor</td><td valign="top">23.3</td><td valign="top">1923.2</td><td valign="top">−80.1</td><td valign="top">−6.3</td><td valign="top">5.4E-33</td></tr><tr><td valign="top"><italic>TFPI</italic></td><td valign="top">Tissue factor pathway inhibitor</td><td valign="top">3.4</td><td valign="top">0.4</td><td valign="top">7.7</td><td valign="top">2.9</td><td valign="top">8.7E-19</td></tr><tr><td valign="top"><italic>THBD</italic></td><td valign="top">Thrombomodulin</td><td valign="top">9.6</td><td valign="top">224.0</td><td valign="top">−22.2</td><td valign="top">−4.5</td><td valign="top">3.2E-48</td></tr><tr><td valign="top"><italic>VWF</italic></td><td valign="top">Von Willebrand factor</td><td valign="top">14.5</td><td valign="top">7.7</td><td valign="top">2.0</td><td valign="top">1.0</td><td valign="top">2.0E-05</td></tr></tbody></table></table-wrap></sec></sec><sec id="s2-2"><title>Changes in transcripts encoding extrinsic pathway proteins that initiate thrombin generation</title><sec id="s2-2-1"><title>Overview of pathways examined</title><p>The integral cytoplasmic membrane protein tissue factor (TF, encoded by <italic>F3</italic>) is the primary initiator of thrombin generation in vivo. In many inflammatory conditions, cellular TF expression is upregulated (<xref ref-type="bibr" rid="bib10">Edwards et al., 1979</xref>), providing a mechanistic explanation for hypercoagulable states associated with a variety of bacterial and viral infections (<xref ref-type="bibr" rid="bib19">Grover and Mackman, 2018</xref>; <xref ref-type="bibr" rid="bib29">Levi and van der Poll, 2017</xref>). Tissue factor pathway inhibitor (TFPI, encoded by <italic>TFPI</italic>) is a Kunitz-type protease inhibitor produced by vascular endothelium (<xref ref-type="bibr" rid="bib3">Bajaj et al., 1990</xref>) and is the major inhibitor of the factor VIIa (FVIIa)/TF complex (<xref ref-type="bibr" rid="bib64">Wood et al., 2014</xref>).</p></sec><sec id="s2-2-2"><title>Study findings</title><p>Surprisingly, transcripts encoding TF were similar in COVID-19 and control BALF samples (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="table" rid="table1">Table 1</xref>), whereas transcripts for TFPI were increased eightfold in COVID-19 BALF. On balance, these data indicate that pulmonary fibrin deposition does not stem from enhanced local TF production and that counterintuitively, COVID-19 may dampen TF-dependent mechanisms in the lungs.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Transcriptional changes in lung induced by COVID-19 infection did not alter <italic>F3</italic>, but decreased aPC anticoagulant capacity, suggesting decreased inhibition of the propagation phase of coagulation.</title><p>Figure shows differential gene expression (log<sub>2</sub> fold change) of coagulation pathway transcripts in BALF of COVID-19 patients; the image illustrates mechanistic relationships of the protein products of the identified transcripts during coagulation. Shading indicates relative expression in COVID-19 patients compared to controls: increased (red) or decreased (blue). There was minimal change in <italic>F3</italic> (encoding tissue factor ) and increased <italic>TFPI</italic> (encoding the major inhibitor of tissue factor activity). There was decreased <italic>THBD</italic>, <italic>PROCR</italic>, and <italic>PROS1</italic> (encoding proteins that enhance anticoagulant activity) and increased <italic>SERPINA5</italic> (encoding protein C inhibitor). There was also decreased <italic>SERPING1</italic> (encoding C1-Inhibitor). Other transcripts showing changes (e.g., F11, F10, F7, F2) encode proteins typically produced in the liver; local expression of these proteins is unclear.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64330-fig1-v3.tif"/></fig></sec></sec><sec id="s2-3"><title>Changes in transcripts encoding intrinsic pathway proteins that initiate thrombin generation</title><sec id="s2-3-1"><title>Overview of pathways examined</title><p>Increased thrombin generation can also be initiated by the plasma protease FXIIa (<xref ref-type="bibr" rid="bib31">Maas and Renné, 2018</xref>; <xref ref-type="bibr" rid="bib54">Stavrou, 2018</xref>). While FXIIa does not contribute to hemostasis, it is implicated in thrombo-inflammatory conditions. FXIIa converts factor XI (FXI, encoded by <italic>F11</italic>) to the protease FXIa (<xref ref-type="bibr" rid="bib24">Ivanov et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Long et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Schmaier, 2016</xref>; <xref ref-type="bibr" rid="bib60">Wang et al., 2019</xref>), a potent activator of the coagulation protease factor IX (FIX, encoded by <italic>F9</italic>) (<xref ref-type="bibr" rid="bib38">Mohammed et al., 2018</xref>).</p></sec><sec id="s2-3-2"><title>Study findings</title><p>Transcripts encoding FXII were slightly decreased (−4-fold) in COVID-19 and control BALF samples (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="table" rid="table1">Table 1</xref>), but the expression of the C1 inhibitor (encoded by <italic>SERPING1</italic>), which normally inhibits the FXII protein activity, is downregulated 80-fold. While it is not known if pulmonary tissues normally produce FXI or FIX, transcripts for FXI (81-fold) and FIX (190-fold) were both increased in BALF from COVID-19 patients. Numerous studies have reported correlations between plasma FIX and FXI levels and risk for venous thromboembolism and ischemic stroke (<xref ref-type="bibr" rid="bib2">Ammollo et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Folsom et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Mohammed et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Preis et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Salomon et al., 2011</xref>, <xref ref-type="bibr" rid="bib46">Salomon et al., 2008</xref>; <xref ref-type="bibr" rid="bib52">Siegerink et al., 2010</xref>; <xref ref-type="bibr" rid="bib57">Suri et al., 2010</xref>). Perhaps local increases in FIX or FXI expression enhance thrombin generation and promote thrombus formation.</p></sec></sec><sec id="s2-4"><title>Changes in transcripts encoding anticoagulant proteins</title><sec id="s2-4-1"><title>Overview of pathways examined</title><p>Healthy lung endothelium has membrane-associated anticoagulant proteins that inhibit different points in the thrombin generation pathway. These include TFPI, which inhibits the initiation of coagulation as described above, and thrombomodulin (encoded by <italic>THBD</italic>) and endothelial protein C receptor (EPCR, encoded by <italic>PROCR</italic>), which coordinate to inhibit the propagation of coagulation. Thrombomodulin captures thrombin and converts it from a procoagulant enzyme to an activator of protein C (encoded by <italic>PROC</italic>) in a process enhanced by binding of PC to EPCR. Activated PC with its cofactor protein S (encoded by <italic>PROS1</italic>) downregulates thrombin generation by inactivating factors VIIIa and Va and produces a cytoprotective/anti-inflammatory effect when bound to EPCR through cleavage of protease activated receptor-1 on endothelial cells (<xref ref-type="bibr" rid="bib23">Ito et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Riewald et al., 2002</xref>).</p></sec><sec id="s2-4-2"><title>Study findings</title><p>Transcripts encoding thrombomodulin (−22-fold) and EPCR (−33-fold) were each reduced in BALF from COVID-19 patients compared with controls (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="table" rid="table1">Table 1</xref>), suggesting SARS-CoV-2 is associated with reduced expression of these proteins on vascular endothelium. We also observed a marked increase in protein C transcripts in BALF from COVID-19 patients (227-fold), but a significant reduction in PS transcripts (−54-fold). Since protein C and protein S in blood are primarily synthesized by hepatocytes, the importance of local synthesis of these proteins is not known. However, expression patterns in BALF are consistent with the observation that the plasma concentration of protein C is moderately elevated, and protein S moderately reduced, in COVID-19 patients (<xref ref-type="bibr" rid="bib39">Panigada et al., 2020</xref>). In COVID-19 BALF, there was also a substantial increase (786-fold) in mRNA for protein C inhibitor (encoded by <italic>SERPINA5</italic>), a serpin regulator of activated protein C. Taken as a whole, the transcript pattern in COVID-19 BALF suggests a diminished capacity of the endothelial anticoagulant system to downregulate local thrombin generation.</p></sec></sec><sec id="s2-5"><title>Changes in transcripts that encode fibrinogen and proteins in the fibrinolytic pathway</title><sec id="s2-5-1"><title>Overview of pathways examined</title><p>The fibrinolytic system is responsible for enzymatic degradation of fibrin. Plasminogen activators convert plasminogen to plasmin, which cleaves fibrin and generates fibrin degradation products, including the circulating biomarker D-dimer. Cells within the lung express plasminogen activators (e.g., [tPA, encoded by <italic>PLAT</italic>], urokinase plasminogen activator [uPA, encoded by <italic>PLAU</italic>], and the uPA receptor [uPAR, encoded by <italic>PLAUR</italic>]) that prevent fibrin accumulation in small airways and the alveolar compartment and that maintain blood vessel patency (<xref ref-type="bibr" rid="bib51">Shetty et al., 2008</xref>). uPA and uPAR are expressed by lung epithelial cells, alveolar macrophages, and fibroblasts, and reduced expression of these proteins contributes to acute lung injury (<xref ref-type="bibr" rid="bib51">Shetty et al., 2008</xref>). The plasminogen activators are inhibited by plasminogen activator inhibitor-1 (PAI-1, encoded by <italic>SERPINE1</italic>). Plasma fibrinogen, a dimer of trimers (Aα<sub>2</sub>Bβ<sub>2</sub>γ<sub>2</sub>) encoded by three genes, <italic>FGA</italic>, <italic>FGB</italic>, and <italic>FGG</italic>, is synthesized primarily by hepatocytes (<xref ref-type="bibr" rid="bib40">Pieters and Wolberg, 2019</xref>); however, synthesis has been reported in stimulated cultured lung alveolar epithelial cells and in alveolar epithelium in an animal model of bacterial pneumonia (<xref ref-type="bibr" rid="bib21">Guadiz et al., 1997</xref>; <xref ref-type="bibr" rid="bib53">Simpson-Haidaris et al., 1998</xref>).</p></sec><sec id="s2-5-2"><title>Study findings</title><p>Transcripts encoding the fibrinogen chains were increased in COVID-19 BALF (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>; ). Our findings suggest that local fibrinogen expression in the lungs of COVID-19 patients, like fibrinogen expression by hepatocytes, is upregulated during the acute phase response and may provide additional substrate for local thrombin-mediated fibrin production. Our analysis uncovered evidence of reduced expression of transcripts encoding uPA (−37-fold) and uPAR (−42-fold) (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>) in BALF from COVID-19 patients. Expression of transcripts encoding tPA was very low in BALF from healthy individuals. Transcripts encoding tPA were elevated (fivefold) in COVID-19 BALF, but absolute expression was low compared to uPA and uPAR transcripts in uninfected controls (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). Similarly, expression of transcript for plasminogen (encoded by <italic>PLG</italic>) was elevated in COVID-19 BALF but remained low compared to other transcripts. The combination of increased fibrinogen expression and reduced production of uPA and uPAR indicates a loss of local fibrinolytic capacity, consistent with a lung environment permissive of the accumulation of fibrin deposits within pulmonary vessels and the alveolar space (<xref ref-type="bibr" rid="bib28">Lax et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Magro et al., 2020</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Transcriptional changes in lung induced by COVID-19 infection decreased <italic>PLAU</italic> and <italic>PLAUR</italic>, suggesting diminished fibrinolytic activity.</title><p>Figure shows differential gene expression (log<sub>2</sub> fold change) of fibrinolytic pathway transcripts in BALF of COVID-19 patients; the image illustrates mechanistic relationships of the protein products of the identified transcripts during fibrinolysis. Shading indicates relative expression in COVID-19 patients compared to controls: increased (red) or decreased (blue). There was a moderate increase in <italic>PLAT</italic> (encoding tPA). There was also enhanced expression of <italic>FGB</italic>, <italic>FGA</italic>, and <italic>FGG</italic> (encoding fibrinogen chains) and decreased expression of <italic>PLAU</italic> and <italic>PLAUR</italic> (encoding uPA and uPAR, respectively). Other transcripts showing changes (e.g., <italic>F2, PLG</italic>) encode proteins typically produced in the liver; local expression of these proteins is unclear.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64330-fig2-v3.tif"/></fig></sec></sec><sec id="s2-6"><title>Conclusions</title><p>We detected pronounced changes in mRNA levels encoding proteins involved in regulation of coagulation, fibrinolysis, and inflammation in the lungs of COVID-19 patients. These changes include reductions in transcripts for proteins known to be expressed in normal pulmonary tissue (thrombomodulin, EPCR, uPA, uPAR) that would compromise the functions of anticoagulant and fibrinolytic pathways. In concert with enhanced production of bradykinin and vascular permeability, these changes are likely to create an environment in which plasma proteins are exposed to the extravascular space, resulting in increased fibrin production and reduced fibrin degradation, enabling the fibrin deposits in pulmonary vessels and alveolar spaces observed in autopsies of COVID-19 patients (<xref ref-type="bibr" rid="bib9">Dolhnikoff et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Fox et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Geerdes-Fenge et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Lax et al., 2020</xref>), and contributing to the virulence of the virus.</p><p>An unexpected finding was the lack of change in transcripts for <italic>F3</italic>, which encodes TF, the integral membrane protein responsible for triggering thrombin generation during hemostasis. TF expression is enhanced in a wide range of thrombo-inflammatory disorders, and its over-expression is thought to be important for driving consumptive coagulation. The apparent lack of increase in <italic>F3</italic>, coupled with an apparent increase in <italic>TFPI</italic> transcripts, raises the possibility that pathways unrelated to the FVIIa/TF complex may play a significant role in COVID-19-associated thrombosis. In this regard, thrombomodulin and EPCR transcripts were substantially decreased, suggesting reduced capacity of the lung endothelium to downregulate the propagation of thrombin generation. In addition, changes in regulation or activation of the plasma kallikrein–kinin system and contact activation may be important. This is consistent with our hypothesis that COVID-19 triggers a bradykinin storm (<xref ref-type="bibr" rid="bib16">Garvin et al., 2020</xref>), the net effect of increased bradykinin production, reduced BK degradation, and increased local expression of bradykinin receptors, is expected to enhance vasodilation and vascular permeability, exposing blood components to extravascular proteins that promote fibrin formation and contribute to tissue damage.</p><p>Fibrin deposits and thrombi have been observed in organs other than the lungs in COVID-19 patients, including kidney (<xref ref-type="bibr" rid="bib55">Su et al., 2020</xref>) and spleen (<xref ref-type="bibr" rid="bib35">Mestres et al., 2020</xref>). It is tempting to speculate that transcriptional changes observed in BALF may occur in these other tissues. Currently, it is not clear whether fibrin deposition in specific organs indicates localized infection of those organs, perhaps stemming from differential distribution of the SARS-CoV-2 receptor ACE2, or reflects organ susceptibility to systemic changes induced by the infection. Analysis of transcriptional and proteomic changes in different organs in concert with information on virus entry into parenchymal cells may help explain the pattern of organ-specific thrombosis during SARS-CoV-2 infection.</p><p>Our study has limitations. Although we detected changes in multiple gene transcripts, we did not identify specific cell types for each transcript, which may include lung parenchymal cells, leukocytes, megakaryocytes (<xref ref-type="bibr" rid="bib15">Fox et al., 2020</xref>), and other cells present in native and inflammatory states that undergo transcriptional changes in response to infection. Single-cell analyses will be required to better understand these changes during SARS-CoV-2 infection. As with all transcriptional data, we could not determine whether changes in mRNA manifest as changes in protein expression. While histologic analyses clearly demonstrate fibrin deposition in the lung, further studies using agnostic and targeted proteomics, as well as biochemical analyses will be needed to confirm causation. We focused on changes in coagulation and fibrinolytic pathways in the present study; however, the pathologic processes observed in the lungs of COVID-19 patients are likely to be influenced by changes in other pathways, such as those involving complement. Crosstalk between coagulation, fibrinolytic, and complement pathways is well documented (<xref ref-type="bibr" rid="bib12">Ewald and Eisenberg, 1995</xref>; <xref ref-type="bibr" rid="bib13">Foley et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Fox et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Kleniewski and Donaldson, 1987</xref>). Despite these limitations, it is instructive to consider how the changes in coagulation and fibrinolytic gene expression documented in our study of BALF may represent common events occurring in multiple vascular beds in COVID-19, as identification of a common dysfunction may reveal a targetable mechanism to prevent thrombosis in these patients.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><sec id="s3-1"><title>Study participants</title><p>The nine BALF samples from 5 patients used in this study were collected from patients in Wuhan, China. All patients displayed pneumonia and other severe symptoms upon admission to the hospital in Wuhan, China, in late December 2019 and were therefore admitted to the ICU (<xref ref-type="table" rid="table2">Table 2</xref>). They were originally used for RNA sequencing to identify the etiological agent for COVID-19 and to determine the genomic sequence of SARS-CoV-2. Human mRNA sequences from these samples were used to develop our bradykinin storm model (<xref ref-type="bibr" rid="bib16">Garvin et al., 2020</xref>), but have not previously been analyzed to understand localized coagulopathy in the lungs of patients with COVID-19 (<xref ref-type="bibr" rid="bib68">Zhou et al., 2020b</xref>). We compared mRNA transcripts for proteins involved in coagulation, fibrinolysis, and kinin formation in BALF from these samples with those from 40 controls from a study on the contribution of obesity to disease severity in asthmatics (<xref ref-type="bibr" rid="bib36">Michalovich et al., 2019</xref>). The 40 control individuals included smokers and non-smokers, asthmatics and non-asthmatics, as well as obese and non-obese individuals. Given this diverse set of morbidities and the resulting variance in gene expression, they represent an informative control for patients with COVID-19 as statistically significant changes detected due to COVID-19 are not just representing subtle shifts in variance (<xref ref-type="table" rid="table1">Table 1</xref>). Expression datasets are available from the NCBI Sequence Read Archive under the accession numbers PRJNA605983 (severe acute respiratory syndrome coronavirus 2 raw sequence reads) and PRJNA434133 (Microbiome and Inflammatory Interactions in Obese and Severe Asthmatic Adults).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Clinical data for patients from which BALF was extracted and analyzed for this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">GISAID accession</th><th valign="bottom">Isolate</th><th valign="bottom">NCBI accession</th><th valign="bottom">SRA accessions</th><th valign="bottom">Swab date</th><th valign="bottom">Age</th><th valign="bottom">Sex</th><th valign="bottom">Patient no</th><th valign="bottom">Date onset</th><th valign="bottom">Symptoms_admission</th><th valign="bottom">Status 1/13/20</th><th valign="bottom">Diagnosis history</th></tr></thead><tbody><tr><td valign="bottom">EPI_ISL_402127</td><td valign="bottom">WIV02</td><td valign="bottom">MN996527</td><td valign="bottom">SRR11092058, SRR11092063</td><td valign="bottom">12/30/19</td><td valign="bottom">32</td><td valign="bottom">Male</td><td valign="bottom">ICU-04</td><td valign="bottom">12/19/19</td><td valign="bottom">Fever, cough, dyspnea</td><td valign="bottom">Fever, intermitttent cough</td><td valign="bottom">Negative</td></tr><tr><td valign="bottom">EPI_ISL_402124</td><td valign="bottom">WIV04</td><td valign="bottom">MN996528</td><td valign="bottom">SRR11092057, SRR11092062</td><td valign="bottom">12/30/19</td><td valign="bottom">49</td><td valign="bottom">Female</td><td valign="bottom">ICU-06</td><td valign="bottom">12/27/19</td><td valign="bottom">Fever (37.9C), palpitation</td><td valign="bottom">Fever, malaise, cough</td><td valign="bottom">Coronavirus (nt)</td></tr><tr><td valign="bottom">EPI_ISL_402128</td><td valign="bottom">WIV05</td><td valign="bottom">MN996529</td><td valign="bottom">SRR11092061</td><td valign="bottom">12/30/19</td><td valign="bottom">52</td><td valign="bottom">Female</td><td valign="bottom">ICU-08</td><td valign="bottom">12/22/19</td><td valign="bottom">Fever (38C), expectoration, malaise, dyspnea</td><td valign="bottom">Recovered, disharged</td><td valign="bottom"><italic>Streptococcus pneumoniae</italic> (nt)</td></tr><tr><td valign="bottom">EPI_ISL_402129</td><td valign="bottom">WIV06</td><td valign="bottom">MN996530</td><td valign="bottom">SRR11092056, SRR11092060</td><td valign="bottom">12/30/19</td><td valign="bottom">40</td><td valign="bottom">Male</td><td valign="bottom">ICU-09</td><td valign="bottom">12/28/20</td><td valign="bottom">Fever (38C), expectoration</td><td valign="bottom">Fever (38C), expectoration, dizziness</td><td valign="bottom">Negative</td></tr><tr><td valign="bottom">EPI_ISL_402130</td><td valign="bottom">WIV07</td><td valign="bottom">MN996531</td><td valign="bottom">SRR11092059, SRR11092064</td><td valign="bottom">12/30/19</td><td valign="bottom">56</td><td valign="bottom">Male</td><td valign="bottom">ICU-10</td><td valign="bottom">12/20/19</td><td valign="bottom">Fever, dyspnea, chest tightness</td><td valign="bottom">Fever, malaise, cough, dyspnea</td><td valign="bottom">Negative</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><title>Gene expression analysis</title><p>The CLC Genomics Workbench (20.0.3) was used to trim FASTQ files downloaded from the NCBI Sequence Read Archive to remove any adapter sequences or other artifacts from processing. The RNA reads were mapped to the GRCh38_latest_rna.fna version of the human transcriptome. Mapping parameters included a cost penalty of two for mismatches and three for small insertions or deletions (INDEL), and similarity and length fraction were both set to 0.95. The resulting transcript profiles were manually inspected to account for expression artifacts, such as reads mapping solely to repetitive elements such as the <italic>Alu</italic> transposable element. Transcripts whose counts came solely from (or were dominated by) reads at repetitive elements were removed from the analysis. Where transcripts per million (TPM) values were zero (transcripts were not detected), we used the lowest TPM across samples to two decimal places. If all samples in a group had no detected transcripts, we used the lowest TPM to two decimal places from the entire set of genes queried. The edgeR package (<xref ref-type="bibr" rid="bib34">McCarthy et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">Robinson et al., 2010</xref>) was used to identify genes that were differentially expressed in COVID-19 patient samples compared to controls. Count data were scaled to normalize for library size and normalization factors determined as instructed in edgeR documentation. Dispersion was estimated, and the read counts for each gene were fit with a negative binomial model. Each gene was tested for differential expression. The Benjamini–Hochberg method was used to determine the false discovery rate.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to acknowledge funding from the Oak Ridge National Laboratory, Laboratory Directed Research and Development Fund, LOIS:10074 (which supported the systems biology work), and the National Institutes of Health, U24 HL148865: the LungMap Consortium (which supported tissue and cell-based expression conceptualization). Funding was also provided by the National Institutes of Health grants HL068835 (AM), HL143403 (AW), HL126974 (AW), 3RF1AG053303-01S2 (DJ), and HL140025 (DG) to support analyses and interpretation of the coagulation and fibrinolytic pathways. This research used resources of the Oak Ridge Leadership Computing Facility, which is a DOE Office of Science User Facility supported under Contract DE-AC05-00OR22725. This research used resources of the Compute and Data Environment for Science (CADES) at the Oak Ridge National Laboratory.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>receives research funding from Novo Nordisk and has received honoraria for serving on Novo Nordisk advisory boards.</p></fn><fn fn-type="COI-statement" id="conf2"><p>receives research funding from Takeda and Bristol Myers Squibb</p></fn><fn fn-type="COI-statement" id="conf3"><p>receives research funding from Bayer and has received honoraria for serving on Anthos, Bristol-Myers Squibb, Ionis and Janssen advisory boards.</p></fn><fn fn-type="COI-statement" id="conf4"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Visualization</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-64330-transrepform-v3.pdf"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Data for control and COVID-19 bronchoalveolar lavage samples are available in the Sequence Read Archive at NCBI.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>HR</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>HD</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>RD</given-names></name><name><surname>Liu</surname><given-names>MQ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>XR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>XS</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>QJ</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>LL</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>FX</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Xiao</surname><given-names>GF</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Severe acute respiratory syndrome coronavirus 2 Raw sequence reads</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA605983/">PRJNA605983</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>GlaxoSmithKline</collab></person-group><year iso-8601-date="2018">2018</year><data-title>Microbiome and Inflammatory Interactions in Obese and Severe Asthmatic Adults</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA434133/">PRJNA434133</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname> <given-names>T</given-names></name><name><surname>Chong</surname> <given-names>JM</given-names></name><name><surname>Nakajima</surname> <given-names>N</given-names></name><name><surname>Sano</surname> <given-names>M</given-names></name><name><surname>Yamazaki</surname> <given-names>J</given-names></name><name><surname>Miyamoto</surname> <given-names>I</given-names></name><name><surname>Nishioka</surname> <given-names>H</given-names></name><name><surname>Akita</surname> <given-names>H</given-names></name><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Kataoka</surname> <given-names>M</given-names></name><name><surname>Katano</surname> <given-names>H</given-names></name><name><surname>Tobiume</surname> <given-names>M</given-names></name><name><surname>Sekizuka</surname> <given-names>T</given-names></name><name><surname>Itokawa</surname> <given-names>K</given-names></name><name><surname>Kuroda</surname> <given-names>M</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19, japan</article-title><source>Emerging Infectious Diseases</source><volume>26</volume><fpage>2157</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.3201/eid2609.201353</pub-id><pub-id pub-id-type="pmid">32412897</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammollo</surname> <given-names>CT</given-names></name><name><surname>Semeraro</surname> <given-names>F</given-names></name><name><surname>Colucci</surname> <given-names>M</given-names></name><name><surname>Simioni</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Factor IX-Padua enhances the fibrinolytic resistance of plasma clots</article-title><source>Thrombosis and Haemostasis</source><volume>111</volume><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1160/TH13-06-0489</pub-id><pub-id pub-id-type="pmid">24136406</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajaj</surname> <given-names>MS</given-names></name><name><surname>Kuppuswamy</surname> <given-names>MN</given-names></name><name><surname>Saito</surname> <given-names>H</given-names></name><name><surname>Spitzer</surname> <given-names>SG</given-names></name><name><surname>Bajaj</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis</article-title><source>PNAS</source><volume>87</volume><fpage>8869</fpage><lpage>8873</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.22.8869</pub-id><pub-id pub-id-type="pmid">2247459</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname> <given-names>LM</given-names></name><name><surname>Duval</surname> <given-names>EJ</given-names></name><name><surname>Stroberg</surname> <given-names>E</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Mukhopadhyay</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 autopsies, Oklahoma, USA</article-title><source>American Journal of Clinical Pathology</source><volume>153</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1093/ajcp/aqaa062</pub-id><pub-id pub-id-type="pmid">32275742</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname> <given-names>PJ</given-names></name><name><surname>Christiansen</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hereditary angioedema</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>1136</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1808012</pub-id><pub-id pub-id-type="pmid">32187470</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>N</given-names></name><name><surname>Zhou</surname> <given-names>M</given-names></name><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Qu</surname> <given-names>J</given-names></name><name><surname>Gong</surname> <given-names>F</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Xia</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>The Lancet</source><volume>395</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname> <given-names>M</given-names></name><name><surname>Zuraw</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Angioedema due to bradykinin dysregulation</article-title><source>The Journal of Allergy and Clinical Immunology: In Practice</source><volume>6</volume><fpage>1132</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2018.04.022</pub-id><pub-id pub-id-type="pmid">30033914</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davin</surname> <given-names>L</given-names></name><name><surname>Marechal</surname> <given-names>P</given-names></name><name><surname>Lancellotti</surname> <given-names>P</given-names></name><name><surname>Martinez</surname> <given-names>C</given-names></name><name><surname>Pierard</surname> <given-names>L</given-names></name><name><surname>Radermecker</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors</article-title><source>Acta Cardiologica</source><volume>74</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1080/00015385.2018.1507477</pub-id><pub-id pub-id-type="pmid">30328786</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolhnikoff</surname> <given-names>M</given-names></name><name><surname>Duarte-Neto</surname> <given-names>AN</given-names></name><name><surname>de Almeida Monteiro</surname> <given-names>RA</given-names></name><name><surname>da Silva</surname> <given-names>LFF</given-names></name><name><surname>de Oliveira</surname> <given-names>EP</given-names></name><name><surname>Saldiva</surname> <given-names>PHN</given-names></name><name><surname>Mauad</surname> <given-names>T</given-names></name><name><surname>Negri</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><fpage>1517</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1111/jth.14844</pub-id><pub-id pub-id-type="pmid">32294295</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Rickles</surname> <given-names>FR</given-names></name><name><surname>Bobrove</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Mononuclear cell tissue factor: cell of origin and requirements for activation</article-title><source>Blood</source><volume>54</volume><fpage>359</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1182/blood.V54.2.359.359</pub-id><pub-id pub-id-type="pmid">454843</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Entrenas Castillo</surname> <given-names>M</given-names></name><name><surname>Entrenas Costa</surname> <given-names>LM</given-names></name><name><surname>Vaquero Barrios</surname> <given-names>JM</given-names></name><name><surname>Alcalá Díaz</surname> <given-names>JF</given-names></name><name><surname>López Miranda</surname> <given-names>J</given-names></name><name><surname>Bouillon</surname> <given-names>R</given-names></name><name><surname>Quesada Gomez</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>&quot;Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study&quot;</article-title><source>The Journal of Steroid Biochemistry and Molecular Biology</source><volume>203</volume><elocation-id>105751</elocation-id><pub-id pub-id-type="doi">10.1016/j.jsbmb.2020.105751</pub-id><pub-id pub-id-type="pmid">32871238</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewald</surname> <given-names>GA</given-names></name><name><surname>Eisenberg</surname> <given-names>PR</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Plasmin-mediated activation of contact system in response to pharmacological thrombolysis</article-title><source>Circulation</source><volume>91</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.91.1.28</pub-id><pub-id pub-id-type="pmid">7805216</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname> <given-names>JH</given-names></name><name><surname>Walton</surname> <given-names>BL</given-names></name><name><surname>Aleman</surname> <given-names>MM</given-names></name><name><surname>O'Byrne</surname> <given-names>AM</given-names></name><name><surname>Lei</surname> <given-names>V</given-names></name><name><surname>Harrasser</surname> <given-names>M</given-names></name><name><surname>Foley</surname> <given-names>KA</given-names></name><name><surname>Wolberg</surname> <given-names>AS</given-names></name><name><surname>Conway</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complement activation in arterial and venous thrombosis is mediated by plasmin</article-title><source>EBioMedicine</source><volume>5</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.02.011</pub-id><pub-id pub-id-type="pmid">27077125</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folsom</surname> <given-names>AR</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Roetker</surname> <given-names>NS</given-names></name><name><surname>Heckbert</surname> <given-names>SR</given-names></name><name><surname>Cushman</surname> <given-names>M</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prospective study of circulating factor XI and incident venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)</article-title><source>American Journal of Hematology</source><volume>90</volume><fpage>1047</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1002/ajh.24168</pub-id><pub-id pub-id-type="pmid">26260105</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Fox</surname> <given-names>SE</given-names></name><name><surname>Akmatbekov</surname> <given-names>A</given-names></name><name><surname>Harbert</surname> <given-names>JL</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Quincy Brown</surname> <given-names>J</given-names></name><name><surname>Vander Heide</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pulmonary and cardiac pathology in Covid-19: the first autopsy series from new orleans</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.06.20050575</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvin</surname> <given-names>MR</given-names></name><name><surname>Alvarez</surname> <given-names>C</given-names></name><name><surname>Miller</surname> <given-names>JI</given-names></name><name><surname>Prates</surname> <given-names>ET</given-names></name><name><surname>Walker</surname> <given-names>AM</given-names></name><name><surname>Amos</surname> <given-names>BK</given-names></name><name><surname>Mast</surname> <given-names>AE</given-names></name><name><surname>Justice</surname> <given-names>A</given-names></name><name><surname>Aronow</surname> <given-names>B</given-names></name><name><surname>Jacobson</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm</article-title><source>eLife</source><volume>9</volume><elocation-id>e59177</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59177</pub-id><pub-id pub-id-type="pmid">32633718</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname> <given-names>L</given-names></name><name><surname>Coppola</surname> <given-names>S</given-names></name><name><surname>Cressoni</surname> <given-names>M</given-names></name><name><surname>Busana</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>S</given-names></name><name><surname>Chiumello</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 does not lead to a “Typical” Acute Respiratory Distress Syndrome</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>201</volume><fpage>1299</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1164/rccm.202003-0817LE</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerdes-Fenge</surname> <given-names>HF</given-names></name><name><surname>Reisinger</surname> <given-names>EC</given-names></name><name><surname>Arndt</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pulmonary artery embolism in COVID-19 despite thrombosis prophylaxis</article-title><source>Deutsches Aerzteblatt Online</source><volume>117</volume><elocation-id>297</elocation-id><pub-id pub-id-type="doi">10.3238/arztebl.2020.0297</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname> <given-names>SP</given-names></name><name><surname>Mackman</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue factor: an essential mediator of hemostasis and trigger of thrombosis</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume><fpage>709</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309846</pub-id><pub-id pub-id-type="pmid">29437578</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>L</given-names></name><name><surname>Deng</surname> <given-names>H</given-names></name><name><surname>Ren</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Dai</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamic changes in the microbiome and mucosal immune microenvironment of the lower respiratory tract by influenza virus infection</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>2491</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02491</pub-id><pub-id pub-id-type="pmid">31736922</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guadiz</surname> <given-names>G</given-names></name><name><surname>Sporn</surname> <given-names>LA</given-names></name><name><surname>Goss</surname> <given-names>RA</given-names></name><name><surname>Lawrence</surname> <given-names>SO</given-names></name><name><surname>Marder</surname> <given-names>VJ</given-names></name><name><surname>Simpson-Haidaris</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Polarized secretion of fibrinogen by lung epithelial cells</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>17</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.17.1.2730</pub-id><pub-id pub-id-type="pmid">9224210</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helms</surname> <given-names>J</given-names></name><name><surname>Tacquard</surname> <given-names>C</given-names></name><name><surname>Severac</surname> <given-names>F</given-names></name><name><surname>Leonard-Lorant</surname> <given-names>I</given-names></name><name><surname>Ohana</surname> <given-names>M</given-names></name><name><surname>Delabranche</surname> <given-names>X</given-names></name><name><surname>Merdji</surname> <given-names>H</given-names></name><name><surname>Clere-Jehl</surname> <given-names>R</given-names></name><name><surname>Schenck</surname> <given-names>M</given-names></name><name><surname>Fagot Gandet</surname> <given-names>F</given-names></name><name><surname>Fafi-Kremer</surname> <given-names>S</given-names></name><name><surname>Castelain</surname> <given-names>V</given-names></name><name><surname>Schneider</surname> <given-names>F</given-names></name><name><surname>Grunebaum</surname> <given-names>L</given-names></name><name><surname>Anglés-Cano</surname> <given-names>E</given-names></name><name><surname>Sattler</surname> <given-names>L</given-names></name><name><surname>Mertes</surname> <given-names>P-M</given-names></name><name><surname>Meziani</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study</article-title><source>Intensive Care Medicine</source><volume>46</volume><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-06062-x</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname> <given-names>T</given-names></name><name><surname>Thachil</surname> <given-names>J</given-names></name><name><surname>Asakura</surname> <given-names>H</given-names></name><name><surname>Levy</surname> <given-names>JH</given-names></name><name><surname>Iba</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential</article-title><source>Critical Care</source><volume>23</volume><elocation-id>280</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-019-2552-0</pub-id><pub-id pub-id-type="pmid">31416465</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname> <given-names>I</given-names></name><name><surname>Shakhawat</surname> <given-names>R</given-names></name><name><surname>Sun</surname> <given-names>MF</given-names></name><name><surname>Dickeson</surname> <given-names>SK</given-names></name><name><surname>Puy</surname> <given-names>C</given-names></name><name><surname>McCarty</surname> <given-names>OJ</given-names></name><name><surname>Gruber</surname> <given-names>A</given-names></name><name><surname>Matafonov</surname> <given-names>A</given-names></name><name><surname>Gailani</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nucleic acids as cofactors for factor XI and prekallikrein activation: different roles for high-molecular-weight kininogen</article-title><source>Thrombosis and Haemostasis</source><volume>117</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1160/TH16-09-0691</pub-id><pub-id pub-id-type="pmid">28124063</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakieła</surname> <given-names>B</given-names></name><name><surname>Gielicz</surname> <given-names>A</given-names></name><name><surname>Plutecka</surname> <given-names>H</given-names></name><name><surname>Przybyszowski</surname> <given-names>M</given-names></name><name><surname>Soja</surname> <given-names>J</given-names></name><name><surname>Sładek</surname> <given-names>K</given-names></name><name><surname>Bochenek</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bronchoalveolar lavage transcriptome and eicosanoid profiles reveal heterogeneity of lower airway inflammation in aspirin-exacerbated respiratory disease (AERD)</article-title><source>Allergy and Immunology</source><volume>52</volume><elocation-id>PA5010</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.congress-2018.pa5010</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname> <given-names>N</given-names></name><name><surname>Granzow</surname> <given-names>M</given-names></name><name><surname>Meister</surname> <given-names>M</given-names></name><name><surname>Muley</surname> <given-names>T</given-names></name><name><surname>Herth</surname> <given-names>FJF</given-names></name><name><surname>Kreuter</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptome analysis in endobronchial epithelial lining fluid compared to bronchoalveolar lavage in idiopathic pulmonary fibrosis</article-title><source>Pneumologie</source><volume>69</volume><elocation-id>1556653</elocation-id><pub-id pub-id-type="doi">10.1055/s-0035-1556653</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleniewski</surname> <given-names>J</given-names></name><name><surname>Donaldson</surname> <given-names>VH</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin A revised method of purification of high molecular weight kininogen</article-title><source>The Journal of Laboratory and Clinical Medicine</source><volume>109</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">2950194</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lax</surname> <given-names>SF</given-names></name><name><surname>Skok</surname> <given-names>K</given-names></name><name><surname>Zechner</surname> <given-names>P</given-names></name><name><surname>Kessler</surname> <given-names>HH</given-names></name><name><surname>Kaufmann</surname> <given-names>N</given-names></name><name><surname>Koelblinger</surname> <given-names>C</given-names></name><name><surname>Vander</surname> <given-names>K</given-names></name><name><surname>Bargfrieder</surname> <given-names>U</given-names></name><name><surname>Trauner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pulmonary arterial thrombosis in COVID-19 with fatal outcome : results from a prospective, Single-Center, clinicopathologic case series</article-title><source>Annals of Internal Medicine</source><volume>173</volume><fpage>350</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.7326/M20-2566</pub-id><pub-id pub-id-type="pmid">32422076</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname> <given-names>M</given-names></name><name><surname>van der Poll</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Coagulation and sepsis</article-title><source>Thrombosis Research</source><volume>149</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2016.11.007</pub-id><pub-id pub-id-type="pmid">27886531</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname> <given-names>AT</given-names></name><name><surname>Kenne</surname> <given-names>E</given-names></name><name><surname>Jung</surname> <given-names>R</given-names></name><name><surname>Fuchs</surname> <given-names>TA</given-names></name><name><surname>Renné</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Contact system revisited: an interface between inflammation, coagulation, and innate immunity</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>14</volume><fpage>427</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1111/jth.13235</pub-id><pub-id pub-id-type="pmid">26707513</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname> <given-names>C</given-names></name><name><surname>Renné</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Coagulation factor XII in thrombosis and inflammation</article-title><source>Blood</source><volume>131</volume><fpage>1903</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-04-569111</pub-id><pub-id pub-id-type="pmid">29483100</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magro</surname> <given-names>C</given-names></name><name><surname>Mulvey</surname> <given-names>JJ</given-names></name><name><surname>Berlin</surname> <given-names>D</given-names></name><name><surname>Nuovo</surname> <given-names>G</given-names></name><name><surname>Salvatore</surname> <given-names>S</given-names></name><name><surname>Harp</surname> <given-names>J</given-names></name><name><surname>Baxter-Stoltzfus</surname> <given-names>A</given-names></name><name><surname>Laurence</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases</article-title><source>Translational Research</source><volume>220</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.007</pub-id><pub-id pub-id-type="pmid">32299776</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marceau</surname> <given-names>F</given-names></name><name><surname>Bachelard</surname> <given-names>H</given-names></name><name><surname>Bouthillier</surname> <given-names>J</given-names></name><name><surname>Fortin</surname> <given-names>JP</given-names></name><name><surname>Morissette</surname> <given-names>G</given-names></name><name><surname>Bawolak</surname> <given-names>MT</given-names></name><name><surname>Charest-Morin</surname> <given-names>X</given-names></name><name><surname>Gera</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bradykinin receptors: agonists, antagonists, expression, signaling, and adaptation to sustained stimulation</article-title><source>International Immunopharmacology</source><volume>82</volume><elocation-id>106305</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106305</pub-id><pub-id pub-id-type="pmid">32106060</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>4288</fpage><lpage>4297</lpage><pub-id pub-id-type="doi">10.1093/nar/gks042</pub-id><pub-id pub-id-type="pmid">22287627</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestres</surname> <given-names>G</given-names></name><name><surname>Puigmacià</surname> <given-names>R</given-names></name><name><surname>Blanco</surname> <given-names>C</given-names></name><name><surname>Yugueros</surname> <given-names>X</given-names></name><name><surname>Esturrica</surname> <given-names>M</given-names></name><name><surname>Riambau</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Risk of peripheral arterial thrombosis in COVID-19</article-title><source>Journal of Vascular Surgery</source><volume>72</volume><fpage>756</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2020.04.477</pub-id><pub-id pub-id-type="pmid">32417015</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalovich</surname> <given-names>D</given-names></name><name><surname>Rodriguez-Perez</surname> <given-names>N</given-names></name><name><surname>Smolinska</surname> <given-names>S</given-names></name><name><surname>Pirozynski</surname> <given-names>M</given-names></name><name><surname>Mayhew</surname> <given-names>D</given-names></name><name><surname>Uddin</surname> <given-names>S</given-names></name><name><surname>Van Horn</surname> <given-names>S</given-names></name><name><surname>Sokolowska</surname> <given-names>M</given-names></name><name><surname>Altunbulakli</surname> <given-names>C</given-names></name><name><surname>Eljaszewicz</surname> <given-names>A</given-names></name><name><surname>Pugin</surname> <given-names>B</given-names></name><name><surname>Barcik</surname> <given-names>W</given-names></name><name><surname>Kurnik-Lucka</surname> <given-names>M</given-names></name><name><surname>Saunders</surname> <given-names>KA</given-names></name><name><surname>Simpson</surname> <given-names>KD</given-names></name><name><surname>Schmid-Grendelmeier</surname> <given-names>P</given-names></name><name><surname>Ferstl</surname> <given-names>R</given-names></name><name><surname>Frei</surname> <given-names>R</given-names></name><name><surname>Sievi</surname> <given-names>N</given-names></name><name><surname>Kohler</surname> <given-names>M</given-names></name><name><surname>Gajdanowicz</surname> <given-names>P</given-names></name><name><surname>Graversen</surname> <given-names>KB</given-names></name><name><surname>Lindholm Bøgh</surname> <given-names>K</given-names></name><name><surname>Jutel</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>JR</given-names></name><name><surname>Akdis</surname> <given-names>CA</given-names></name><name><surname>Hessel</surname> <given-names>EM</given-names></name><name><surname>O'Mahony</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5711</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13751-9</pub-id><pub-id pub-id-type="pmid">31836714</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middeldorp</surname> <given-names>S</given-names></name><name><surname>Coppens</surname> <given-names>M</given-names></name><name><surname>van Haaps</surname> <given-names>TF</given-names></name><name><surname>Foppen</surname> <given-names>M</given-names></name><name><surname>Vlaar</surname> <given-names>AP</given-names></name><name><surname>Müller</surname> <given-names>MCA</given-names></name><name><surname>Bouman</surname> <given-names>CCS</given-names></name><name><surname>Beenen</surname> <given-names>LFM</given-names></name><name><surname>Kootte</surname> <given-names>RS</given-names></name><name><surname>Heijmans</surname> <given-names>J</given-names></name><name><surname>Smits</surname> <given-names>LP</given-names></name><name><surname>Bonta</surname> <given-names>PI</given-names></name><name><surname>van Es</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Incidence of venous thromboembolism in hospitalized patients with COVID-19</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><fpage>1995</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1111/jth.14888</pub-id><pub-id pub-id-type="pmid">32369666</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname> <given-names>BM</given-names></name><name><surname>Matafonov</surname> <given-names>A</given-names></name><name><surname>Ivanov</surname> <given-names>I</given-names></name><name><surname>Sun</surname> <given-names>MF</given-names></name><name><surname>Cheng</surname> <given-names>Q</given-names></name><name><surname>Dickeson</surname> <given-names>SK</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Verhamme</surname> <given-names>IM</given-names></name><name><surname>Emsley</surname> <given-names>J</given-names></name><name><surname>Gailani</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An update on factor XI structure and function</article-title><source>Thrombosis Research</source><volume>161</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2017.10.008</pub-id><pub-id pub-id-type="pmid">29223926</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panigada</surname> <given-names>M</given-names></name><name><surname>Bottino</surname> <given-names>N</given-names></name><name><surname>Tagliabue</surname> <given-names>P</given-names></name><name><surname>Grasselli</surname> <given-names>G</given-names></name><name><surname>Novembrino</surname> <given-names>C</given-names></name><name><surname>Chantarangkul</surname> <given-names>V</given-names></name><name><surname>Pesenti</surname> <given-names>A</given-names></name><name><surname>Peyvandi</surname> <given-names>F</given-names></name><name><surname>Tripodi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><fpage>1738</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1111/jth.14850</pub-id><pub-id pub-id-type="pmid">32302438</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieters</surname> <given-names>M</given-names></name><name><surname>Wolberg</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fibrinogen and fibrin: an illustrated review</article-title><source>Research and Practice in Thrombosis and Haemostasis</source><volume>3</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1002/rth2.12191</pub-id><pub-id pub-id-type="pmid">31011700</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prada</surname> <given-names>AE</given-names></name><name><surname>Zahedi</surname> <given-names>K</given-names></name><name><surname>Davis</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Regulation of C1 inhibitor synthesis</article-title><source>Immunobiology</source><volume>199</volume><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0171-2985(98)80042-9</pub-id><pub-id pub-id-type="pmid">9777421</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preis</surname> <given-names>M</given-names></name><name><surname>Hirsch</surname> <given-names>J</given-names></name><name><surname>Kotler</surname> <given-names>A</given-names></name><name><surname>Zoabi</surname> <given-names>A</given-names></name><name><surname>Stein</surname> <given-names>N</given-names></name><name><surname>Rennert</surname> <given-names>G</given-names></name><name><surname>Saliba</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events</article-title><source>Blood</source><volume>129</volume><fpage>1210</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-742262</pub-id><pub-id pub-id-type="pmid">28039189</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revenko</surname> <given-names>AS</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Crosby</surname> <given-names>JR</given-names></name><name><surname>Bhattacharjee</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>May</surname> <given-names>C</given-names></name><name><surname>Gailani</surname> <given-names>D</given-names></name><name><surname>Monia</surname> <given-names>BP</given-names></name><name><surname>MacLeod</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding</article-title><source>Blood</source><volume>118</volume><fpage>5302</fpage><lpage>5311</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-05-355248</pub-id><pub-id pub-id-type="pmid">21821705</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riewald</surname> <given-names>M</given-names></name><name><surname>Petrovan</surname> <given-names>RJ</given-names></name><name><surname>Donner</surname> <given-names>A</given-names></name><name><surname>Mueller</surname> <given-names>BM</given-names></name><name><surname>Ruf</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Activation of endothelial cell protease activated receptor 1 by the protein C pathway</article-title><source>Science</source><volume>296</volume><fpage>1880</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1126/science.1071699</pub-id><pub-id pub-id-type="pmid">12052963</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MD</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname> <given-names>O</given-names></name><name><surname>Steinberg</surname> <given-names>DM</given-names></name><name><surname>Koren-Morag</surname> <given-names>N</given-names></name><name><surname>Tanne</surname> <given-names>D</given-names></name><name><surname>Seligsohn</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Reduced incidence of ischemic stroke in patients with severe factor XI deficiency</article-title><source>Blood</source><volume>111</volume><fpage>4113</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-10-120139</pub-id><pub-id pub-id-type="pmid">18268095</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname> <given-names>O</given-names></name><name><surname>Steinberg</surname> <given-names>DM</given-names></name><name><surname>Zucker</surname> <given-names>M</given-names></name><name><surname>Varon</surname> <given-names>D</given-names></name><name><surname>Zivelin</surname> <given-names>A</given-names></name><name><surname>Seligsohn</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis</article-title><source>Thrombosis and Haemostasis</source><volume>105</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1160/TH10-05-0307</pub-id><pub-id pub-id-type="pmid">21057700</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmaier</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>14</volume><fpage>28</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/jth.13194</pub-id><pub-id pub-id-type="pmid">26565070</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmaier</surname> <given-names>AH</given-names></name><name><surname>Emsley</surname> <given-names>J</given-names></name><name><surname>Feener</surname> <given-names>EP</given-names></name><name><surname>Gailani</surname> <given-names>D</given-names></name><name><surname>Govers-Riemslag</surname> <given-names>JWP</given-names></name><name><surname>Kaplan</surname> <given-names>AP</given-names></name><name><surname>Maas</surname> <given-names>C</given-names></name><name><surname>Morrissey</surname> <given-names>JH</given-names></name><name><surname>Renné</surname> <given-names>T</given-names></name><name><surname>Sidelmann</surname> <given-names>JJ</given-names></name><name><surname>Meijers</surname> <given-names>JCM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nomenclature of factor XI and the contact system</article-title><source>Journal of Thrombosis and Haemostasis : JTH</source><volume>17</volume><fpage>2216</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1111/jth.14595</pub-id><pub-id pub-id-type="pmid">31410964</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Tang</surname> <given-names>SY</given-names></name><name><surname>Devine</surname> <given-names>JC</given-names></name><name><surname>Anderson</surname> <given-names>ST</given-names></name><name><surname>Nayak</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>SL</given-names></name><name><surname>Valenzuela</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>DG</given-names></name><name><surname>Grant</surname> <given-names>GR</given-names></name><name><surname>López</surname> <given-names>CB</given-names></name><name><surname>FitzGerald</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Circadian control of lung inflammation in influenza infection</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4107</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11400-9</pub-id><pub-id pub-id-type="pmid">31511530</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname> <given-names>S</given-names></name><name><surname>Padijnayayveetil</surname> <given-names>J</given-names></name><name><surname>Tucker</surname> <given-names>T</given-names></name><name><surname>Stankowska</surname> <given-names>D</given-names></name><name><surname>Idell</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability</article-title><source>American Journal of Physiology-Lung Cellular and Molecular Physiology</source><volume>295</volume><fpage>L967</fpage><lpage>L975</lpage><pub-id pub-id-type="doi">10.1152/ajplung.90349.2008</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegerink</surname> <given-names>B</given-names></name><name><surname>Govers-Riemslag</surname> <given-names>JW</given-names></name><name><surname>Rosendaal</surname> <given-names>FR</given-names></name><name><surname>Ten Cate</surname> <given-names>H</given-names></name><name><surname>Algra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the risk of arterial thrombosis in relation to oral contraceptives (RATIO) case-control study</article-title><source>Circulation</source><volume>122</volume><fpage>1854</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.943738</pub-id><pub-id pub-id-type="pmid">20956210</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson-Haidaris</surname> <given-names>PJ</given-names></name><name><surname>Courtney</surname> <given-names>MA</given-names></name><name><surname>Wright</surname> <given-names>TW</given-names></name><name><surname>Goss</surname> <given-names>R</given-names></name><name><surname>Harmsen</surname> <given-names>A</given-names></name><name><surname>Gigliotti</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia</article-title><source>Infection and Immunity</source><volume>66</volume><fpage>4431</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.1128/IAI.66.9.4431-4439.1998</pub-id><pub-id pub-id-type="pmid">9712798</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavrou</surname> <given-names>EX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Factor XII in inflammation and wound healing</article-title><source>Current Opinion in Hematology</source><volume>25</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000450</pub-id><pub-id pub-id-type="pmid">29994899</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>M</given-names></name><name><surname>Wan</surname> <given-names>C</given-names></name><name><surname>Yi</surname> <given-names>LX</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>HY</given-names></name><name><surname>Yi</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>HC</given-names></name><name><surname>Fogo</surname> <given-names>AB</given-names></name><name><surname>Nie</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China</article-title><source>Kidney International</source><volume>98</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.04.003</pub-id><pub-id pub-id-type="pmid">32327202</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Fang</surname> <given-names>L</given-names></name><name><surname>Roth</surname> <given-names>M</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Papakonstantinou</surname> <given-names>E</given-names></name><name><surname>Zhai</surname> <given-names>W</given-names></name><name><surname>Louis</surname> <given-names>R</given-names></name><name><surname>Heinen</surname> <given-names>V</given-names></name><name><surname>Schleich</surname> <given-names>FN</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Savic</surname> <given-names>S</given-names></name><name><surname>Tamm</surname> <given-names>M</given-names></name><name><surname>Stolz</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts</article-title><source>European Respiratory Journal</source><volume>54</volume><elocation-id>1900300</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.00300-2019</pub-id><pub-id pub-id-type="pmid">31467116</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suri</surname> <given-names>MFK</given-names></name><name><surname>Yamagishi</surname> <given-names>K</given-names></name><name><surname>Aleksic</surname> <given-names>N</given-names></name><name><surname>Hannan</surname> <given-names>PJ</given-names></name><name><surname>Folsom</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Novel hemostatic factor levels and risk of ischemic stroke: the atherosclerosis risk in communities (ARIC) Study</article-title><source>Cerebrovascular Diseases</source><volume>29</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1159/000297966</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/jth.14768</pub-id><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Veerdonk</surname> <given-names>FL</given-names></name><name><surname>Kouijzer</surname> <given-names>IJE</given-names></name><name><surname>de Nooijer</surname> <given-names>AH</given-names></name><name><surname>van der Hoeven</surname> <given-names>HG</given-names></name><name><surname>Maas</surname> <given-names>C</given-names></name><name><surname>Netea</surname> <given-names>MG</given-names></name><name><surname>Brüggemann</surname> <given-names>RJM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19</article-title><source>JAMA Network Open</source><volume>3</volume><elocation-id>e2017708</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.17708</pub-id><pub-id pub-id-type="pmid">32789513</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Ivanov</surname> <given-names>I</given-names></name><name><surname>Smith</surname> <given-names>SA</given-names></name><name><surname>Gailani</surname> <given-names>D</given-names></name><name><surname>Morrissey</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Polyphosphate, Zn<sup>2+</sup> and high molecular weight kininogen modulate individual reactions of the contact pathway of blood clotting</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>17</volume><fpage>2131</fpage><lpage>2140</lpage><pub-id pub-id-type="doi">10.1111/jth.14612</pub-id><pub-id pub-id-type="pmid">31420909</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Hajizadeh</surname> <given-names>N</given-names></name><name><surname>Moore</surname> <given-names>EE</given-names></name><name><surname>McIntyre</surname> <given-names>RC</given-names></name><name><surname>Moore</surname> <given-names>PK</given-names></name><name><surname>Veress</surname> <given-names>LA</given-names></name><name><surname>Yaffe</surname> <given-names>MB</given-names></name><name><surname>Moore</surname> <given-names>HB</given-names></name><name><surname>Barrett</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><fpage>1752</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1111/jth.14828</pub-id><pub-id pub-id-type="pmid">32267998</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weigt</surname> <given-names>SS</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Palchevskiy</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Patel</surname> <given-names>N</given-names></name><name><surname>Ross</surname> <given-names>DJ</given-names></name><name><surname>Reynolds</surname> <given-names>J</given-names></name><name><surname>Shah</surname> <given-names>PD</given-names></name><name><surname>Danziger-Isakov</surname> <given-names>LA</given-names></name><name><surname>Sweet</surname> <given-names>SC</given-names></name><name><surname>Singer</surname> <given-names>LG</given-names></name><name><surname>Budev</surname> <given-names>M</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Belperio</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection</article-title><source>The Journal of Heart and Lung Transplantation</source><volume>38</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2019.05.001</pub-id><pub-id pub-id-type="pmid">31122726</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group</collab><name><surname>Sterne</surname> <given-names>JAC</given-names></name><name><surname>Murthy</surname> <given-names>S</given-names></name><name><surname>Diaz</surname> <given-names>JV</given-names></name><name><surname>Slutsky</surname> <given-names>AS</given-names></name><name><surname>Villar</surname> <given-names>J</given-names></name><name><surname>Angus</surname> <given-names>DC</given-names></name><name><surname>Annane</surname> <given-names>D</given-names></name><name><surname>Azevedo</surname> <given-names>LCP</given-names></name><name><surname>Berwanger</surname> <given-names>O</given-names></name><name><surname>Cavalcanti</surname> <given-names>AB</given-names></name><name><surname>Dequin</surname> <given-names>PF</given-names></name><name><surname>Du</surname> <given-names>B</given-names></name><name><surname>Emberson</surname> <given-names>J</given-names></name><name><surname>Fisher</surname> <given-names>D</given-names></name><name><surname>Giraudeau</surname> <given-names>B</given-names></name><name><surname>Gordon</surname> <given-names>AC</given-names></name><name><surname>Granholm</surname> <given-names>A</given-names></name><name><surname>Green</surname> <given-names>C</given-names></name><name><surname>Haynes</surname> <given-names>R</given-names></name><name><surname>Heming</surname> <given-names>N</given-names></name><name><surname>Higgins</surname> <given-names>JPT</given-names></name><name><surname>Horby</surname> <given-names>P</given-names></name><name><surname>Jüni</surname> <given-names>P</given-names></name><name><surname>Landray</surname> <given-names>MJ</given-names></name><name><surname>Le Gouge</surname> <given-names>A</given-names></name><name><surname>Leclerc</surname> <given-names>M</given-names></name><name><surname>Lim</surname> <given-names>WS</given-names></name><name><surname>Machado</surname> <given-names>FR</given-names></name><name><surname>McArthur</surname> <given-names>C</given-names></name><name><surname>Meziani</surname> <given-names>F</given-names></name><name><surname>Møller</surname> <given-names>MH</given-names></name><name><surname>Perner</surname> <given-names>A</given-names></name><name><surname>Petersen</surname> <given-names>MW</given-names></name><name><surname>Savovic</surname> <given-names>J</given-names></name><name><surname>Tomazini</surname> <given-names>B</given-names></name><name><surname>Veiga</surname> <given-names>VC</given-names></name><name><surname>Webb</surname> <given-names>S</given-names></name><name><surname>Marshall</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a Meta-analysis</article-title><source>Jama</source><volume>324</volume><fpage>1330</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.17023</pub-id><pub-id pub-id-type="pmid">32876694</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname> <given-names>JP</given-names></name><name><surname>Ellery</surname> <given-names>PE</given-names></name><name><surname>Maroney</surname> <given-names>SA</given-names></name><name><surname>Mast</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Biology of tissue factor pathway inhibitor</article-title><source>Blood</source><volume>123</volume><fpage>2934</fpage><lpage>2943</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-11-512764</pub-id><pub-id pub-id-type="pmid">24620349</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Tai</surname> <given-names>Y</given-names></name><name><surname>Bai</surname> <given-names>C</given-names></name><name><surname>Gao</surname> <given-names>T</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Xia</surname> <given-names>P</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>The Lancet Respiratory Medicine</source><volume>8</volume><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>HH</given-names></name><name><surname>Li</surname> <given-names>CX</given-names></name><name><surname>Tang</surname> <given-names>LF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The differential expression profiles of miRNA-let 7a, 7b, and 7c in bronchoalveolar lavage fluid from infants with asthma and airway foreign bodies</article-title><source>Journal of Evidence-Based Integrative Medicine</source><volume>24</volume><elocation-id>2515690X18821906</elocation-id><pub-id pub-id-type="doi">10.1177/2515690X18821906</pub-id><pub-id pub-id-type="pmid">30789054</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>Du</surname> <given-names>R</given-names></name><name><surname>Fan</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Xiang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>B</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Guan</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Tu</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Cao</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>The Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>XL</given-names></name><name><surname>Wang</surname> <given-names>XG</given-names></name><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Si</surname> <given-names>HR</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Huang</surname> <given-names>CL</given-names></name><name><surname>Chen</surname> <given-names>HD</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>RD</given-names></name><name><surname>Liu</surname> <given-names>MQ</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Shen</surname> <given-names>XR</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>XS</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>QJ</given-names></name><name><surname>Deng</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>LL</given-names></name><name><surname>Yan</surname> <given-names>B</given-names></name><name><surname>Zhan</surname> <given-names>FX</given-names></name><name><surname>Wang</surname> <given-names>YY</given-names></name><name><surname>Xiao</surname> <given-names>GF</given-names></name><name><surname>Shi</surname> <given-names>ZL</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64330.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript captivated the connection between COVID-19 and cardiovascular disease. Following their previous studies, the authors further investigate the dysregulation of the coagulation and fibrinolytic pathways on COVID-19 patients. The authors' conclusions are well supported, and the authors draw on deep expertise in the field to make exquisite use of gene expression data to obtain deep insights into COVID-19 pathogenesis.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SARS-CoV-2 Suppresses Anticoagulant and Fibrinolytic Gene Expression in the Lung&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Jos van der Meer as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>This manuscript extends the authors previous work using transcriptomics data to formulate their &quot;bradykinin storm&quot; hypothesis. Their previous work was extremely high-impact, as it challenged the dogma that a cytokine storm was the principle mechanisms underlying lung pathology in COVID-19. This manuscript further extends their prior work, linking bradykinin signaling to the accumulation of fibrin deposits within pulmonary vessels and the alveolar space, inferred from gene expression data from COVID-19 patients. The authors' conclusions are well supported, and the authors draw on deep expertise in the field to make exquisite use of gene expression data to obtain deep insights into COVID-19 pathogenesis.</p><p>Essential Revisions:</p><p>1) The reviewer acknowledges the extensive expertise of the impressive author group and congratulates the authors for an interesting investigation. That being said, the reviewer does not think your Abstract reflects the importance or insight of your findings, as your conclusion in the Abstract states &quot;analysis documents increased vascular permeability, enhanced coagulation, and reduced fibrinolytic activity in the lungs of patients with COVID-19&quot;. The potential for acute lung injury, hypercoagulability, and microvascular thrombotic sequela of COVID 19 are well known. the reviewer thinks you need to include some of your important aspects of the investigation's findings in the Abstract rather than generalized conclusions.</p><p>2) The route of viral entry into the body to the respiratory tract initially triggers the local inflammatory response in the lung, with a host defense mechanism of microvascular thrombotic sequela due to microcirculatory injury, but as the disease progresses without any potential immunity, then multiple other organs may be involved. Again, with the initial insult to the lung and subsequent systemic responses that seem to be the sort of chronology of the infection, as a result, it would be helpful to include some time course of the disease progression that you describe. For example, the skin and other organ involvement is a later, not initial event in most patients. the reviewer thinks your Introduction could be shortened with the extensive literature that exists already about COVID 19 coagulopathy, but also, it would be helpful to provide some sense of the time course of the disease progression. The bronchial alveolar lavage specimens you have our impatience intubated and ventilated most likely, and clearly in an advance disease state. The reviewer thinks that needs to be specifically explained as well.</p><p>3) In the subsection “Conclusions”, your first three sentences, including the goal of the present study, need to be incorporated in your Introduction. The reviewer would start your conclusion section with the sentence &quot;We detected pronounced changes in mRNA levels encoding proteins involved in regulation of coagulation, fibrinolysis, and inflammation in the lungs of COVID-19 patients.&quot;.</p><p>4) Gene and protein naming conventions: when specific proteins or hormones are listed in the text, it would be helpful to also list their formal names, e.g., the reviewer assumes that &quot;tissue factor&quot; in the Abstract refers to human protein CD142 – though later the informal name is given as &quot;extravascular tissue factor (TF)&quot;. The informal name, however, is confusing since TF is also the formal symbol for the gene &quot;<italic>Homo sapiens</italic> transferrin (TF)&quot;, RefSeq NM_001354704. It would be particularly helpful to list both gene and protein names parenthetically at each such mention. While this is less valuable for those who study the human system directly, it is very important for biologists specializing in model organisms who may be less familiar with medical parlance and informal gene and protein names. It is also extremely useful for AI/ML algorithms that parse Abstracts in search of gene names.</p><p>5) Introductory material in the Results section: The Results sections begin with lengthy introductions to the biomedical literature surrounding specific pathways, forcing the reader to scan for novel material. It would be better either to move this material to the Introduction with call-outs to specific Results sections, or, alternatively, to label such introductory paragraphs explicitly so that readers already familiar with the literature can quickly scan past them. As is, it took me a few reads to find the novel result within the first paragraph labeled, &quot;Changes in transcripts encoding proteins in the Kallikrein-Kinin/Bradykinin System&quot;.</p><p>6) Speculative discussion in the Results section: The final sentence of the first section of Results is speculative, and would fit better in the Discussion:</p><p>(6a) &quot;Consistent with our hypothesis that COVID-19 triggers a Bradykinin Storm, the net effect of increased BK production, reduced BK degradation, and increased local expression of BK receptors, may be to enhance vasodilation and vascular permeability that expose blood components to extravascular proteins that promote fibrin formation and contribute to tissue damage.&quot;</p><p>Or, alternatively, re-word to posit as a conclusion supported by a combination of data in this study and prior literature, perhaps as follows:</p><p>&quot;Our observations of increased BK production, reduced BK degradation, and increased local expression of BK receptors, are expected in a system undergoing enhanced vasodilation and vascular permeability, where blood components are exposed to extravascular proteins that promote fibrin formation and contribute to tissue damage. Further, these findings are broadly consistent with our hypothesis that COVID-19 triggers a Bradykinin Storm.&quot;</p><p>or something like that – at least get rid of the &quot;…may be to…&quot;.</p><p>(6b) Similarly, we have, &quot;On balance, these data suggest that pulmonary fibrin deposition does not stem from enhanced local TF production and that counterintuitively, COVID-19 may dampen TF-dependent mechanisms in the lungs.&quot;</p><p>It would be better to use &quot;indicate&quot; than &quot;suggest&quot;, or to rephrase something like:</p><p>&quot;On balance, these data are inconsistent pulmonary fibrin deposition from enhanced local TF production – but are consistent, if perhaps counterintuitively, with the hypothesis that COVID-19 dampens TF-dependent mechanisms in the lungs.&quot;</p><p>(6c) The paragraph that begins, &quot;Increased thrombin generation can also be initiated by the plasma protease factor XIIa (FXIIa).(50, 51)…&quot; Appears to be entirely &quot;Discussion&quot; and should probably be removed from Results. Did I miss a new result there?</p><p>(6d) The last two sentences of the Results section are also quite speculative:</p><p>&quot;The combination of increased fibrinogen expression, reduced production of uPA and uPAR, and a modest increase in PAI-1 suggests a loss of local fibrinolytic capacity. This change may permit the accumulation of fibrin deposits within pulmonary vessels and the alveolar space.&quot;</p><p>How about the following instead?:</p><p>&quot;The combination of increased fibrinogen expression, reduced production of uPA and uPAR, and a modest increase in PAI-1 indicates a loss of local fibrinolytic capacity – consistent with a lung environment permissive of the accumulation of fibrin deposits within pulmonary vessels and the alveolar space (CITE).&quot; and of course a citation should be added where indicated above.</p><p>7) Comments on Figures 1 and 2: please increase the resolution of the figure to at least 300dpi and ensure that all fonts are at least size 9. Providing a color scale would make the data more readable for the reader.</p><p>8) Table 1: Please provide the log2 data for the observed gene. Adding statistical analysis and providing the statistical significance would make the data more convincing.</p><p>9) Materials and methods: In this paper, the authors use 9 COVID-19 patient's BALF samples and 40 control. The reviewer found that in a previous paper (Garvin et al., 2020), the author's group also use the same number of COVID-19 cases and controls. Are these the same samples?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64330.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p><p>1) The reviewer acknowledges the extensive expertise of the impressive author group and congratulates the authors for an interesting investigation. That being said, the reviewer does not think your Abstract reflects the importance or insight of your findings, as your conclusion in the Abstract states &quot;analysis documents increased vascular permeability, enhanced coagulation, and reduced fibrinolytic activity in the lungs of patients with COVID-19&quot;. The potential for acute lung injury, hypercoagulability, and microvascular thrombotic sequela of COVID 19 are well known. the reviewer thinks you need to include some of your important aspects of the investigation's findings in the Abstract rather than generalized conclusions.</p></disp-quote><p>We removed general background information from the Abstract and recapitulated the most important results to make the impact of the work clear.</p><disp-quote content-type="editor-comment"><p>2) The route of viral entry into the body to the respiratory tract initially triggers the local inflammatory response in the lung, with a host defense mechanism of microvascular thrombotic sequela due to microcirculatory injury, but as the disease progresses without any potential immunity, then multiple other organs may be involved. Again, with the initial insult to the lung and subsequent systemic responses that seem to be the sort of chronology of the infection, as a result, it would be helpful to include some time course of the disease progression that you describe. For example, the skin and other organ involvement is a later, not initial event in most patients. the reviewer thinks your Introduction could be shortened with the extensive literature that exists already about COVID 19 coagulopathy, but also, it would be helpful to provide some sense of the time course of the disease progression. The bronchial alveolar lavage specimens you have our impatience intubated and ventilated most likely, and clearly in an advance disease state. The reviewer thinks that needs to be specifically explained as well.</p></disp-quote><p>We made major changes to the Introduction. Overall we shortened the Introduction. Some portions of the first paragraph were moved to the &quot;Overview of pathways examined&quot; sections in the Results and Discussion, while some text from the “Conclusions” subsection was incorporated into this section.</p><p>We added text relating to disease progression to help put our model into context (e.g., Introduction, second paragraph, second sentence). The Results and Discussion have been changed extensively to make our model more clear.</p><p>We added Table 2 with the clinical characteristics of the patients from which the BALF were taken. All were admitted to the ICU, which we note in the new document.</p><p>We added text in the Materials and methods section &quot;Study participants&quot; regarding the severity of illness and the condition of the patients at the time of sampling.</p><disp-quote content-type="editor-comment"><p>3) In the subsection “Conclusions”, your first three sentences, including the goal of the present study, need to be incorporated in your Introduction. The reviewer would start your conclusion section with the sentence &quot;We detected pronounced changes in mRNA levels encoding proteins involved in regulation of coagulation, fibrinolysis, and inflammation in the lungs of COVID-19 patients.&quot;.</p></disp-quote><p>The first 3 sentences from the subsection “Conclusions” were moved to the Introduction.</p><disp-quote content-type="editor-comment"><p>4) Gene and protein naming conventions: when specific proteins or hormones are listed in the text, it would be helpful to also list their formal names, e.g., the reviewer assumes that &quot;tissue factor&quot; in the Abstract refers to human protein CD142 – though later the informal name is given as &quot;extravascular tissue factor (TF)&quot;. The informal name, however, is confusing since TF is also the formal symbol for the gene &quot;<italic>Homo sapiens</italic> transferrin (TF)&quot;, RefSeq NM_001354704. It would be particularly helpful to list both gene and protein names parenthetically at each such mention. While this is less valuable for those who study the human system directly, it is very important for biologists specializing in model organisms who may be less familiar with medical parlance and informal gene and protein names. It is also extremely useful for AI/ML algorithms that parse Abstracts in search of gene names.</p></disp-quote><p>We changed gene and protein names throughout the text to use the formal names and include gene and/or protein symbols parenthetically where appropriate.</p><disp-quote content-type="editor-comment"><p>5) Introductory material in the Results section: The Results sections begin with lengthy introductions to the biomedical literature surrounding specific pathways, forcing the reader to scan for novel material. It would be better either to move this material to the Introduction with call-outs to specific Results sections, or, alternatively, to label such introductory paragraphs explicitly so that readers already familiar with the literature can quickly scan past them. As is, it took me a few reads to find the novel result within the first paragraph labeled, &quot;Changes in transcripts encoding proteins in the Kallikrein-Kinin/Bradykinin System&quot;.</p></disp-quote><p>We separated these sections into subsections for &quot;Overview of pathways examined&quot; and</p><p>&quot;Study findings.&quot;</p><disp-quote content-type="editor-comment"><p>6) Speculative discussion in the Results section: The final sentence of the first section of Results is speculative, and would fit better in the Discussion:</p><p>(6a) &quot;Consistent with our hypothesis that COVID-19 triggers a Bradykinin Storm, the net effect of increased BK production, reduced BK degradation, and increased local expression of BK receptors, may be to enhance vasodilation and vascular permeability that expose blood components to extravascular proteins that promote fibrin formation and contribute to tissue damage.&quot;</p><p>Or, alternatively, re-word to posit as a conclusion supported by a combination of data in this study and prior literature, perhaps as follows:</p><p>&quot;Our observations of increased BK production, reduced BK degradation, and increased local expression of BK receptors, are expected in a system undergoing enhanced vasodilation and vascular permeability, where blood components are exposed to extravascular proteins that promote fibrin formation and contribute to tissue damage. Further, these findings are broadly consistent with our hypothesis that COVID-19 triggers a Bradykinin Storm.&quot;</p><p>or something like that – at least get rid of the &quot;…may be to…&quot;.</p></disp-quote><p>We moved this discussion point to the end of the “Conclusions” subsection.</p><disp-quote content-type="editor-comment"><p>(6b) Similarly, we have, &quot;On balance, these data suggest that pulmonary fibrin deposition does not stem from enhanced local TF production and that counterintuitively, COVID-19 may dampen TF-dependent mechanisms in the lungs.&quot;</p><p>It would be better to use &quot;indicate&quot; than &quot;suggest&quot;, or to rephrase something like:</p><p>&quot;On balance, these data are inconsistent pulmonary fibrin deposition from enhanced local TF production – but are consistent, if perhaps counterintuitively, with the hypothesis that COVID-19 dampens TF-dependent mechanisms in the lungs.&quot;</p></disp-quote><p>We changed the text to &quot;indicate&quot; rather than &quot;suggest.&quot;</p><disp-quote content-type="editor-comment"><p>(6c) The paragraph that begins, &quot;Increased thrombin generation can also be initiated by the plasma protease factor XIIa (FXIIa).(50, 51)…&quot; Appears to be entirely &quot;Discussion&quot; and should probably be removed from Results. Did I miss a new result there?</p></disp-quote><p>We added text to make the results clear; see text beginning with &quot;Transcripts encoding FXII were slightly decreased (-4-fold)…&quot;, which is found in the section &quot;Changes in transcripts encoding intrinsic pathway proteins that initiate thrombin generation&quot; &gt; &quot;Study findings.&quot;</p><disp-quote content-type="editor-comment"><p>(6d) The last two sentences of the Results section are also quite speculative:</p><p>&quot;The combination of increased fibrinogen expression, reduced production of uPA and uPAR, and a modest increase in PAI-1 suggests a loss of local fibrinolytic capacity. This change may permit the accumulation of fibrin deposits within pulmonary vessels and the alveolar space.&quot;</p><p>How about the following instead?:</p><p>&quot;The combination of increased fibrinogen expression, reduced production of uPA and uPAR, and a modest increase in PAI-1 indicates a loss of local fibrinolytic capacity – consistent with a lung environment permissive of the accumulation of fibrin deposits within pulmonary vessels and the alveolar space (CITE).&quot; and of course a citation should be added where indicated above.</p></disp-quote><p>We changed the text as suggested by the reviewer.</p><disp-quote content-type="editor-comment"><p>7) Comments on Figures 1 and 2: please increase the resolution of the figure to at least 300dpi and ensure that all fonts are at least size 9. Providing a color scale would make the data more readable for the reader.</p></disp-quote><p>Fixed resolution and added color scale.</p><disp-quote content-type="editor-comment"><p>8) Table 1: Please provide the log2 data for the observed gene. Adding statistical analysis and providing the statistical significance would make the data more convincing.</p></disp-quote><p>We added the log2-fold-change values and p-values, as well as the name of the protein for each gene.</p><disp-quote content-type="editor-comment"><p>9) Materials and methods: In this paper, the authors use 9 COVID-19 patient's BALF samples and 40 control. The reviewer found that in a previous paper (Garvin et al., 2020), the author's group also use the same number of COVID-19 cases and controls. Are these the same samples?</p></disp-quote><p>We added a table of the sample IDs (data available from NCBI) to help clarify that these are the same samples. This is listed as Table 1.</p></body></sub-article></article>